Background pattern
EPIVIR 150 MG FILM-COATED TABLETS

EPIVIR 150 MG FILM-COATED TABLETS

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use EPIVIR 150 MG FILM-COATED TABLETS

Introduction

Package Leaflet: Information for the User

Epivir 150mg film-coated tablets

lamivudine

Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What Epivir is and what it is used for
  2. What you need to know before you take Epivir
  3. How to take Epivir
  4. Possible side effects
  5. Storing Epivir
  6. Contents of the pack and other information

1. What Epivir is and what it is used for

Epivir is used in the treatment of HIV (Human Immunodeficiency Virus) infection in adults and children.

The active substance of Epivir is lamivudine. Epivir is a type of medicine known as an antiretroviral. It belongs to a group of medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).

Epivir does not completely cure HIV infection; it reduces the amount of virus in the body and keeps it at a low level. It also increases the number of CD4 cells in the blood. CD4 cells are a type of white blood cell that plays an important role in helping your body fight infection.

Not everyone responds to treatment with Epivir in the same way. Your doctor will monitor the effectiveness of your treatment.

2. What you need to know before you take Epivir

Do not take Epivir

  • if you are allergicto lamivudine or any of the other ingredients of this medicine (listed in section 6).

Consult your doctorif you think this applies to you.

Be cautious with Epivir

Some people who take Epivir or other combination treatments for HIV infection have a higher risk of serious side effects. You need to know that there is a higher risk:

  • if you have ever had liver disease, including hepatitis B or C (if you have hepatitis B, do not stop taking Epivir without your doctor's advice, as it may get worse)
  • if you are overweight(especially if you are a woman)
  • if you or your child have kidney disease, your dose may need to be changed.

Consult your doctorif you have any of these conditions. You may need to have extra tests, including blood tests, while taking this medicine (see section 4).

Be aware of important symptoms

Some people who take medicines for HIV infection develop other conditions, which can be serious. You need to know what important signs and symptoms to look out for while taking Epivir.

Read the information under the heading “Other possible side effects of combination therapy for HIV” in section 4 of this leaflet.

Other medicines and Epivir

Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including those obtained without a prescription, and herbal medicines.

Remember to tell your doctor or pharmacist if you start taking any new medicines while taking Epivir.

The following medicines must not be used with Epivir:

  • medicines (usually liquids) that contain sorbitol and other polyalcohols (such as xylitol, mannitol, lactitol, or maltitol), if taken regularly
  • other medicines that contain lamivudine (used to treat HIV infectionor hepatitis B virus infection)
  • emtricitabine (used to treat HIV infection)
  • high doses of co-trimoxazole(a combination of trimethoprim and sulfamethoxazole), an antibiotic
  • cladribine (used to treat hairy cell leukaemia).

Tell your doctorif you are being treated with any of these medicines.

Pregnancy

If you are pregnant, if you become pregnant, or if you are planning to become pregnant, talk to your doctor about the risks and benefits of taking Epivir for both you and your baby.

Epivir and similar medicines may cause side effects in babies during pregnancy.

If you have been taking Epivirduring your pregnancy, your doctor may ask you to have regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit of protection against HIV was greater than the risk of side effects.

Breast-feeding

It is not recommendedthat women with HIV breast-feed their babies because HIV infection can be passed on to the baby through breast milk.

A small amount of the components of Epivir may also pass into breast milk.

If you are breast-feeding or thinking of breast-feeding, you should consult your doctor as soon as possible.

Driving and using machines

Epivir is unlikely to affect your ability to drive or use machines.

Epivir contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per dose unit; this is essentially “sodium-free”.

3. How to take Epivir

Follow exactly the instructions for administration of this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.

Swallow the Epivir tablets with a little water. Epivir can be taken with or without food.

If you cannot swallow the tablets whole, you can break them and mix them with a small amount of food or liquid; take the whole dose immediately.

Stay in regular contact with your doctor

Epivir helps to control your condition. You will need to take it every day to prevent your condition from getting worse. You may develop other infections and illnesses associated with HIV infection.

Stay in contact with your doctor and do not stop taking Epivirwithout talking to your doctor first.

How much to take

Adults, adolescents, and children weighing at least 25 kg:

The usual dose of Epivir is 300 mg per day. It can be taken as one 150 mg tablet twice a day (approximately 12 hours apart), or as two 150 mg tablets once a day, as directed by your doctor.

Children weighing between 20 kg and less than 25 kg:

The usual dose of Epivir is 225 mg per day. It can be given as 75 mg (half a 150 mg tablet) in the morning and 150 mg (one whole tablet) in the evening, or 225 mg (one and a half 150 mg tablets) once a day, as directed by your doctor.

Children weighing between 14 kg and less than 20 kg:

The usual dose of Epivir is 150 mg per day. It can be taken as 75 mg (half a 150 mg tablet) twice a day (approximately 12 hours apart), or 150 mg (one 150 mg tablet) once a day, as directed by your doctor.

Epivir is also available as an oral solution for the treatment of children over 3 months and for patients who cannot swallow tablets or who require a lower dose.

If you or your child have kidney problems, your dose may need to be changed.

Consult your doctorif this applies to you or your child.

If you take more Epivir than you should

If you take more Epivir than you should, tell your doctor or pharmacist, or contact the nearest hospital emergency department. If possible, show them the Epivir packaging.

If you forget to take Epivir

If you forget to take a dose, take it as soon as you remember and then continue with your normal treatment schedule.

Do not take a double dose to make up for forgotten doses.

4. Possible side effects

During treatment for HIV, you may experience an increase in weight and levels of glucose and lipids in the blood. This may be partly due to the recovery of your health and lifestyle, and in the case of lipids in the blood, sometimes to the HIV medicines themselves. Your doctor will monitor these changes.

Like all medicines, this medicine can cause side effects, although not everybody gets them.

When you are being treated for HIV, it can be difficult to tell whether a symptom is a side effect of Epivir or of other medicines you are taking, or if it is due to the HIV disease itself. Therefore, it is very important that you inform your doctor about any changes in your health.

In addition to the side effects listed below for Epivir, other conditions can develop during combination therapy for HIV.

It is important that you read the information under the heading “Other possible side effects of combination therapy for HIV”.

Common side effects

May affect up to 1 in 10people:

  • headache
  • feeling sick (nausea)
  • vomiting
  • diarrhoea
  • stomach pain
  • fatigue, lack of energy
  • fever (high temperature)
  • feeling unwell
  • muscle pain and discomfort
  • joint pain
  • difficulty sleeping (insomnia)
  • cough
  • irritated or runny nose
  • skin rash
  • hair loss (alopecia).

Uncommon side effects

May affect up to 1 in 100people:

The uncommon side effects that may appear in blood tests are:

  • a decrease in the number of cells involved in blood clotting (thrombocytopenia)
  • low red blood cell count (anaemia)or low white blood cell count (neutropenia)
  • an increase in liver enzymes.

Rare side effects

May affect up to 1 in 1,000people:

  • severe allergic reaction that causes swelling of the face, tongue, or throat, which may cause difficulty in swallowing or breathing
  • inflammation of the pancreas (pancreatitis)
  • muscle tissue breakdown
  • inflammation (hepatitis).

A rare side effect that may appear in blood tests is:

  • an increase in an enzyme called amylase.

Very rare side effects

May affect up to 1 in 10,000people:

  • lactic acidosis (excess of lactic acid in the blood)
  • tingling or numbness of the arms, legs, hands, or feet.

A very rare side effect that may appear in blood tests is:

  • failure of the bone marrow to produce new red blood cells (pure red cell aplasia).

If you experience side effects

Tell your doctor or pharmacistif you think any of the side effects you are experiencing are serious or if you notice any side effects not listed in this leaflet.

Other possible side effects of combination therapy for HIV

Combination therapies like Epivir can cause other conditions to develop during treatment for HIV.

Worsening of old infections

People with advanced HIV infection (AIDS) have weak immune systems and are more likely to develop serious infections (opportunistic infections). When these people start treatment, they may find that old, hidden infections flare up, causing signs and symptoms of inflammation. These symptoms are probably due to an improvement in the body's immune response, which enables it to fight off these infections.

In addition to these opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you have started taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms such as muscle weakness, weakness in the hands and feet, and moving up towards the trunk of the body, palpitations, tremor, or hyperactivity, please inform your doctor immediately so that you can receive the necessary treatment.

If you notice any symptoms of infection while taking Epivir:

Tell your doctor immediately. Do not take any other medicine for the infection without your doctor's advice.

You may have problems with your bones

Some people who receive combination therapy for HIV may develop a condition called osteonecrosis. With this condition, part of the bone tissue dies due to a lack of blood supply to the bone. People are more likely to develop this condition:

  • if they have been taking combination therapy for a long time
  • if they are also taking anti-inflammatory medicines called corticosteroids
  • if they drink alcohol
  • if their immune system is very weakened
  • if they are overweight.

Signs of osteonecrosis include:

  • stiffness in the joints
  • pain and discomfort (especially in the hip, knee, or shoulder)
  • difficulty moving.

If you notice any of these symptoms:

Tell your doctor.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storing Epivir

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the carton.

Do not store Epivir above 30°C.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Package Contents and Additional Information

Composition of Epivir

The active ingredient is lamivudine.

The other components are:

  • Core of the tablet: microcrystalline cellulose, sodium carboxymethyl starch (gluten-free), magnesium stearate
    • film coating of the tablet: hypromellose, titanium dioxide, macrogol, and polysorbate 80.

Appearance of Epivir and Package Contents

Epivir 150 mg film-coated tablets are supplied in white polyethylene bottles or blisters containing 60 tablets. The tablets are white, scored, and have a diamond shape with the code "GXCJ7" engraved on both sides.

Marketing Authorization Holder and Manufacturer

Manufacturer

Marketing Authorization Holder

Delpharm Poznan Spólka Akcyjna

ul. Grunwaldzka 189

60-322 Poznan

Poland

ViiV Healthcare BV

Van Asch van Wijckstraat 55H

3811 LP Amersfoort

Netherlands

You can request more information about this medication by contacting the local representative of the marketing authorization holder:

Belgium/Belgique/Belgien

ViiV Healthcare srl/bv

Tel: + 32 (0)10 85 65 00

Lithuania

ViiV Healthcare BV

Tel: + 370 80000334

Bulgaria

ViiV Healthcare BV

Tel: + 359 80018205

Luxembourg/Luxemburg

ViiV Healthcare srl/bv

Belgium/Belgien

Tel: + 32 (0)10 85 65 00

Czech Republic

GlaxoSmithKline s.r.o.

Tel: + 420 222 001 111

cz.info@gsk.com

Hungary

ViiV Healthcare BV

Tel: + 36 80088309

Denmark

GlaxoSmithKline Pharma A/S

Tlf: + 45 36 35 91 00

dk-info@gsk.com

Malta

ViiV Healthcare BV

Tel: + 356 80065004

Germany

ViiV Healthcare GmbH

Tel: + 49 (0)89 203 0038-10

viiv.med.info@viivhealthcare.com

Netherlands

ViiV Healthcare BV

Tel: + 31 (0) 33 2081199

Estonia

ViiV Healthcare BV

Tel: + 372 8002640

estonia@gsk.com

Norway

GlaxoSmithKline AS

Tlf: + 47 22 70 20 00

Greece

GlaxoSmithKline Μονοπρ?σωπη A.E.B.E.

Tel: + 30 210 68 82 100

Austria

GlaxoSmithKline Pharma GmbH

Tel: + 43 (0)1 97075 0

at.info@gsk.com

Spain

Laboratorios ViiV Healthcare, S.L.

Tel: + 34 900 923 501

es-ci@viivhealthcare.com

Poland

GSK Services Sp. z o.o.

Tel: + 48 (0)22 576 9000

France

ViiV Healthcare SAS

Tel: + 33 (0)1 39 17 6969

Infomed@viivhealthcare.com

Portugal

VIIVHIV HEALTHCARE, UNIPESSOAL, LDA.

Tel: + 351 21 094 08 01

viiv.fi.pt@viivhealthcare.com

Croatia

ViiV Healthcare BV

Tel: +385 800787089

Romania

ViiV Healthcare BV

Tel: + 40 800672524

Ireland

GlaxoSmithKline (Ireland) Limited

Tel: + 353 (0)1 4955000

Slovenia

ViiV Healthcare BV

Tel: + 386 80688869

Iceland

Vistor hf.

Tel: +354 535 7000

Slovak Republic

ViiV Healthcare BV

Tel: + 421 800500589

Italy

ViiV Healthcare S.r.l.

Tel: + 39 (0)45 7741600

Finland

GlaxoSmithKline Oy

Tel: + 358 (0)10 30 30 30

Cyprus

ViiV Healthcare BV

Tel: + 357 80070017

Sweden

GlaxoSmithKline AB

Tel: + 46 (0)8 638 93 00

info.produkt@gsk.com

Latvia

ViiV Healthcare BV

Tel: + 371 80205045

United Kingdom (Northern Ireland)

ViiV Healthcare BV Limited

Tel: + 44 (0)800 221441

customercontactuk@gsk.com

Date of the last revision of this prospectus:{MM/AAAA}.

Detailed information about this medication is available on the European Medicines Agency website: http://www.ema.europa.eu

Get updates and exclusive offers

Be the first to know about new services, marketplace updates, and subscriber-only promos.

Follow us on social media
FacebookInstagram
Logo
Oladoctor
Find a doctor
Doctors by specialty
Services
Choose language
© 2025 Oladoctor. All rights reserved.
VisaMastercardStripe